Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm.
The study found that fotemustine resulted in a slightly longer median survival time than DTIC, but also had higher rates of toxicity.